|
We are a clinical stage biotechnology company, focused on leveraging artificial
intelligence ("A.I."), machine learning and genomic data to streamline the drug
development process and to identify the patients that will benefit from our
targeted oncology therapies. Our portfolio of therapies consists of small
molecules that others have tried, but failed, to develop into an approved
commercialized drug, as well as new compounds that we are developing with the
assistance of our proprietary A.I. platform and our biomarker driven approach.
Our A.I.
|
|